IMUGENE CHART. TA only, page-33890

Just some findimgs from the worlds fastest search engine..

Imugene Ltd (ASX: IMU)

Market Cap: AUD 374.8 million

Price-to-Sales (P/S) Ratio: 25.4x1

Price-to-Book (P/B) Ratio: 3.9x2

Recent Performance: 5% increase
....

Peers Comparison
.....

Clinuvel Pharmaceuticals (ASX: CUV)

Market Cap: AUD 735.1 million

P/S Ratio: 9x1

P/B Ratio: 4x2

Estimated Growth: 22.5%
.....

Dimerix (ASX: DXB)

Market Cap: AUD 231.3 million

P/S Ratio: 25.4x1

P/B Ratio: Not available

....

Aroa Biosurgery (ASX: ARX)

Market Cap: AUD 213.4 million

P/S Ratio: 3.4x1

P/B Ratio: Not available

Estimated Growth: 21.7%
.....

PYC Therapeutics (ASX: PYC)

Market Cap: AUD 452.6 million

P/S Ratio: 21.3x1

P/B Ratio: 11.6x2

Estimated Growth: 9.3%
....

Summary

Imugene has a relatively high P/S ratio compared to the peer average (14.8x), indicating it might be considered expensive based on this metric.
....

Clinuvel Pharmaceuticals and Aroa Biosurgery have lower P/S ratios, suggesting they might be more attractively valued in comparison1.

PYC Therapeutics has a high P/B ratio, indicating it might be overvalued based on this metric.
....

Imugene’s strong market cap and recent performance highlight its potential, but its high valuation ratios suggest that investors are paying a premium for its growth prospects.
....